- 130 patients treated with Agenus' PD-1 & CTLA-4; clinical benefit >63% treated - Recent FDA meeting confirms path to BLA filing; targeted for 2020 - Next-Gen CTLA-4 IND filed; four INDs filed year to date - Two INDs for First-In-Class bispecifics on track for year end - Partnership discussions

LEXINGTON, Mass., Oct. 31, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on Tuesday,

- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit 1  in early analyses LEXINGTON, Mass., Oct. 20 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell

- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer - AGEN PD-1 & CTLA-4 (AGEN1884) is the most advanced combination in 2L cervical cancer LEXINGTON, Mass., Oct. 9, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Sept. 28, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a

LEXINGTON, Mass., Sept. 21, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Corporation

- Payment of $5M received for initiation of Phase 1 trial of LAG-3 antibody - Eligible for up to an additional $505 million for milestones plus royalties on sales LEXINGTON, Mass., Sept. 17, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of

LEXINGTON, Mass., Sept. 5 ,  2018 / PRNewswire / -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa, Senior Director, Molecular

LEXINGTON, Mass., Sept. 4, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs

- Payment of $4M received for initiation of phase 1 trial - Up to additional $95 million for milestones plus royalties on sales LEXINGTON, Mass., Aug. 15, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer